Medical

Data from a study recently published by the Royal Marsden Cancer Centre showed promising data for the combination of Avutometinib + Defactinib in the treatment of ovarian cancer, resulting in significant tumour shrinkage in 28% of patients and disease control in 93% of patients.

According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.

The US FDA approved a new treatment for non-small cell lung cancer - Tremelimumab + Durvalumab + platinum-based chemotherapy. The triple combination therapy significantly improves efficacy and patient survival and has a good safety profile.

For many patients after early lung cancer surgery, it is common for them to worry about recurrence. For this reason, many patients tend to undergo CT examinations more closely to ensure that they have not had a recurrence. However, a recent new study conducted by researchers from Washington University School of Medicine in St. Louis found that even with more frequent CT reviews, post-operative outcomes for lung cancer did not improve...

The clinical trial (PARABLE) will take place at 22 sites across the UK and is planned to recruit 192 patients at higher risk of developing heart problems. the PARABLE trial is led by researchers from the Royal Marsden Hospital, the University of Cambridge, and the Institute of Cancer Research (ICR) UK, and is managed by the Clinical Trials and Statistics Unit, funded by Cancer Research UK, at the Institute of Cancer Research (ICR). was conducted.

Who is CinCor?

It is estimated that ninety percent of deaths from breast cancer are caused by complications from metastasis, so how to effectively stop breast cancer metastasis has long been a hot topic in cancer research.

In the last decade, the introduction of several immune checkpoint inhibitors such as CTLA-4/PD-1/PD-L1 and other immune drugs such as Keytruda and Opdivo have marked a major advance in cancer treatment by "liberating" immune T cells and giving them back their ability to attack cancer cells. However, previous data shows that only 10-30% of patients have a good outcome with these immunotherapies

The Mediterranean diet contains mono and polyunsaturated fats from olive oil nuts and fish, polyphenols and fibers from vegetables, fruits and whole grains, which are closely related to the better efficacy of immunotherapeutic drugs called immunocheckpoint inhibitors (ICI).

According to data from cohort 17 of the phase 1b COSMIC-021 trial (NCT03170960), the combination therapy of cabozantinib and atelizumab, at a mean follow-up of 25.9 months, 17% of the 30 patients in cohort 17 had significant tumour shrinkage or disappearance, giving an overall disease control rate of 60% when those with stable lesions were added. 5 patients with tumours in remission All of the patients whose tumours had shrunk by at least 30%.